SAN MARINO, CA – June 19 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today that the Company has been awarded a $400,000 grant by the Lazarex Cancer Foundation to expand and support ongoing cancer gene therapy clinical trials for advanced and metastatic pancreatic cancer.

Rexin-G(TM) is the world’s first targeted injectable gene therapy vector to be approved for use in clinical trials in the USA and abroad. When injected intravenously, Rexin-G(TM) seeks out and destroys metastatic cancer, without the systemic toxicity generally associated with chemotherapy.

Rexin-G recently gained Orphan Drug status as an effective treatment for pancreatic cancer in the United States, and is currently available in clinical trials in Rochester MN.

In a statement to the press, Ms. Dana Dornsife, President of the Lazarex Cancer Foundation said: “We are pleased to provide Epeius Biotechnologies Corporation the funds needed to expedite the development of such promising genetic medicines, which – by improving both the survival and the quality of life – provide cancer patients with more quality time.”

More information:

News issued by: Epeius Biotechnologies Corporation

# # #

Original Story ID: (1748) :: 2006-06-0619-001

Original Keywords: Rexin-G, Lazarex Cancer Foundation, clinical trials in the USA and abroad, destroys metastatic cancer, chemotherapy, Dana Dornsife, Dr. Erlinda M. Gordon, Dr. Frederick L. Hall, California, california news Epeius Biotechnologies Corporation

News Source: Epeius Biotechnologies Corporation